Allergan Confident Data Support Bipolar Depression Addition To Vraylar's Label

After recording its third positive pivotal trial in bipolar depression, Allergan will now file an sNDA for Vraylar in the second half of 2018.

Depression
Allergan Has Good Vraylar Topline Data From 3 Pivotal Bipolar I Depression Studies • Source: Shutterstock

Allergan PLC and Gedeon Richter PLC believe they now have adequate evidence for their atypical antipsychotic drug Vraylar (cariprazine) in the treatment of bipolar I depression to file an sNDA with the FDA in the second half of this year. Vraylar is currently approved for the treatment of schizophrenia in adults and the acute treatment of manic or mixed episodes associated with bipolar I disorder.

The duo said it could now press ahead with the new cariprazine filing armed with positive top-line evidence from three...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: Organon To Pull Plug On OG-6219 Program After Phase II Endometriosis Trial Failure

 

Once hailed as a potential game changer, OG-6219 gets the axe after failing in a Phase II endometriosis-related pain trial.

In Brief: 4DMT Fast-Tracks Long-Acting Wet AMD Therapy Trials, Cuts 25% Of Workforce

 

4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.

In Brief: Atai-Beckley Deal Marches On After Phase II Psychedelic Win

 
• By 

The psychedelic therapy firms pass a key condition for their planned merger after the antidepressant BPL-003 meets the main endpoints of a Phase IIb trial.

More from R&D

In Brief: Atai-Beckley Deal Marches On After Phase II Psychedelic Win

 
• By 

The psychedelic therapy firms pass a key condition for their planned merger after the antidepressant BPL-003 meets the main endpoints of a Phase IIb trial.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

In Brief: Opus Gears Up For FDA Filing In Presbyopia

 

Data from a second pivotal trial support a filing in the US for Opus Genetics’ phentolamine ophthalmic solution, to treat presbyopia.